# Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients

> **NCT03877809** · PHASE2 · COMPLETED · sponsor: **Rare Partners srl Impresa Sociale** · enrollment: 26 (actual)

## Conditions studied

- Beta-Thalassemia

## Interventions

- **DRUG:** Sirolimus 0.5 mg

## Key facts

- **NCT ID:** NCT03877809
- **Lead sponsor:** Rare Partners srl Impresa Sociale
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-27
- **Primary completion:** 2022-04-30
- **Final completion:** 2022-04-30
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2024-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03877809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03877809, "Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03877809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*